glp 1 for chronic kidney disease GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog GLP-1 receptor agonists and next-generation
Description
This personalized approach, combining compounded medication stability knowledge with genetic insights, represents the precision health model PlexusDx emphasizes
Perhaps, satiety is met earlier via GLP-1 drugs
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for chronic weight management) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
The ELAD Phase 2b trial of liraglutide, published in Nature Medicine, randomised 204 patients with mild to moderate disease to daily liraglutide or placebo for 52 weeks
Assess deep tendon reflexes
GLP-1s can increase insulin production, delay gastric emptying, promote beta-cell proliferation, and decrease appetite
